Level C· Early human research exploring benefitsProspective StudyPubMed

Intravenous Administration of Human-Derived Mesenchymal Stem Cell-Conditioned Medium for Patients with General Malaise.

Inami N.

Prospective Study with a reported sample of 19 on Chronic Inflammation, published in J Clin Med (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Clin Med (2025)
Country
Switzerland
Reported sample size
19
Source database
PubMed
PMID
40869710
DOI
10.3390/jcm14165884

Abstract (original English)

Objectives: Animal studies have demonstrated that mesenchymal stem cell-conditioned medium (MSC-CM) possesses various therapeutic effects, including anti-inflammatory and anti-fibrotic properties. This study investigated the efficacy and safety of administering MSC-CM as a treatment for patients with generalized fatigue. Methods: The MSC-CM used in this study was derived from human adipose tissue and umbilical cord-derived mesenchymal stem cells cultured in a medium free of animal-derived components to avoid the risk of infection. This MSC-CM has recently been shown to possess anti-inflammatory effects and has been reported to be safe for human administration. With the expectation of alleviating fatigue symptoms through its anti-inflammatory effects, it was administered to patients intravenously and by inhalation. Safety and changes in subjective symptoms were evaluated, and blood biomarkers related to inflammation and oxidative stress were measured. Results: In this trial involving 19 patients experiencing fatigue, no serious side effects were observed following MSC-CM administration. Nearly half of the patients reported symptom improvement after a single dose, and some exhibited signs of reduced inflammation. Conclusions: This report presents the first investigation of systemic MSC-CM treatment for generalized fatigue, paving the way for more targeted studies on dosage and tr

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research